Search Clinical Trials
Sponsor Condition of Interest |
---|
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR01
Marengo Therapeutics, Inc.
Advanced Solid Tumors
Genital Neoplasm, Female
Urogenital Neoplasms
Lung Neoplasm
Neoplasms by Site
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and
preliminary clinical activity of STAR0602 as a single agent administered intravenously in
participants with advanced solid tumors that are antigen-rich. expand
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich. Type: Interventional Start Date: Jan 2023 |
Contingency Management for Cannabis Use for Persons With HIV
The University of Texas Health Science Center at San Antonio
Marijuana
HIV Infections
The purpose of this study is to determine the feasibility and impact of 28-days of
monitored abstinence from cannabis use on symptoms of depression and anxiety, pain,
sleep, cannabis use withdrawal, HIV viral load and biomarkers of systemic inflammation
among PLWH and who use cannabis regularly (we1 expand
The purpose of this study is to determine the feasibility and impact of 28-days of monitored abstinence from cannabis use on symptoms of depression and anxiety, pain, sleep, cannabis use withdrawal, HIV viral load and biomarkers of systemic inflammation among PLWH and who use cannabis regularly (weekly or more often). This will be a single arm pilot feasibility trial involving a contingency management program to induce cannabis abstinence. Specifically, the contingency management program will provide motivational (monetary) incentives to participants who achieve biochemically verified cannabis abstinence. Over the 28-days of this pilot feasibility trial, participants will attend seven study visits. During these visits, participants will complete survey questionnaires to assess sociodemographic, psychosocial, and behavioral factors. In addition, participants will provide blood and urine specimens for testing and quantitation of HIV viral load, biomarkers of systemic inflammation and for the detection of cannabis and other drugs of abuse. Type: Interventional Start Date: Aug 2021 |
Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)
The University of Texas Health Science Center, Houston
Smoking Cessation
Nicotine Addiction
Schizophrenia
Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive
transcranial magnetic stimulation (rTMS) from F8 coil or active rTMS from H coil for
smoking cessation. Smoking and brain functional connectivity changes will be assessed at
baseline, different stages of rTMS a1 expand
Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from F8 coil or active rTMS from H coil for smoking cessation. Smoking and brain functional connectivity changes will be assessed at baseline, different stages of rTMS and/or follow-ups. Type: Interventional Start Date: Jun 2022 |
RECOVER-AUTONOMIC Platform Protocol
Kanecia Obie Zimmerman
Long COVID
Long Covid19
Long Covid-19
This study is a platform protocol designed to be flexible so that it is suitable for a
wide range of settings within health care systems and in community settings where it can
be integrated into COVID-19 programs and subsequent treatment plans.
This protocol is a prospective, multi-center, multi-a1 expand
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (POTS), in PASC participants. The interventions tested will include non-pharmacologic care and pharmacologic therapies with study drugs. Type: Interventional Start Date: Mar 2024 |
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
Johns Hopkins University
Atrial Fibrillation
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE
design), controlled trial comparing the current Standard Of Care (SOC) of continuous
Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an
AF-sensing Smart Watch (AFSW) in parti1 expand
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk. Type: Interventional Start Date: Jul 2023 |
Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)
Weill Medical College of Cornell University
Emphysema
HIV
The purpose of this study is to determine if doxycycline will reduce progression of
emphysema in people living with HIV.
The secondary objectives are to examine the effects of doxycycline on change in quantity
of emphysema, six minute walk distance, patient reported outcomes, ratio of forced
expir1 expand
The purpose of this study is to determine if doxycycline will reduce progression of emphysema in people living with HIV. The secondary objectives are to examine the effects of doxycycline on change in quantity of emphysema, six minute walk distance, patient reported outcomes, ratio of forced expiratory volume in 1 second and forced vital capacity. Secondary objectives will also describe the safety and tolerability of doxycycline and determine if doxycycline is associated with development of antibiotic-resistant bacterial infections. Type: Interventional Start Date: Aug 2022 |
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Duke University
Cognitive Impairment, Mild
Dementia
Cardiovascular Diseases
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority
study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large
study conducted in community-dwelling older adults without cardiovascular disease (CVD)
or dementia will demonstrate the1 expand
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events. Type: Interventional Start Date: Sep 2020 |
Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression
The University of Texas Health Science Center, Houston
Treatment-resistant Bipolar Depression
The overall objective of the investigators is to assess the therapeutic efficacy and
tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells
(MSCs) isolated from hematogenous bone marrow for treatment of treatment-resistant
bipolar depression patient (TRBD). expand
The overall objective of the investigators is to assess the therapeutic efficacy and tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow for treatment of treatment-resistant bipolar depression patient (TRBD). Type: Interventional Start Date: Apr 2022 |
Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression
The University of Texas Health Science Center, Houston
Major Depressive Disorder
Treatment Resistant Depression
We propose a clinical study of medial forebrain bundle DBS as a treatment in 20 patients
with treatment refractory depression (TRD). Data from the University of Bonn indicates
that surgical lesions of the medical forebrain bundle can produce therapeutic benefits in
patients with depressive disorder1 expand
We propose a clinical study of medial forebrain bundle DBS as a treatment in 20 patients with treatment refractory depression (TRD). Data from the University of Bonn indicates that surgical lesions of the medical forebrain bundle can produce therapeutic benefits in patients with depressive disorders, and suggest that DBS at the same site may also reduce symptomatology in these TRD patients (Schaepfer, 2013). Depression affects up to 10% of the US population and of those at least 10-15% do not benefit from therapies hence why we must explore new treatments. The Percept™ PC system manufactured by Medtronic Neurological will be used in this study. Study subjects will be between the ages of 22 and 70 years of age and suffer from TRD, have failed multiple treatment regimens, including ECT, and remain symptomatic. Those identified as TRD patients will then be enrolled in a clinical pilot study investigating DBS, targeting the MFB. Type: Interventional Start Date: Dec 2013 |
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
Joseph Broderick, MD
Intracerebral Hemorrhage
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time
(FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral
hemorrhage (ICH) within a time window and subgroup of patients that is most likely to
benefit. The central hypothesis is tha1 expand
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. Type: Interventional Start Date: Dec 2021 |
Neuromodulation of the Fear Extinction Circuit Using Temporally and Anatomically Specific TMS in Hu1
The University of Texas Health Science Center, Houston
PTSD
This study aims to explore the mechanisms of how transcranial magnetic stimulation (TMS)
impacts fear circuits. The overarching objectives are to understand how varying TMS
parameters affect targeted brain regions in order to optimize its impact on enhancing
fear extinction memory consolidation in1 expand
This study aims to explore the mechanisms of how transcranial magnetic stimulation (TMS) impacts fear circuits. The overarching objectives are to understand how varying TMS parameters affect targeted brain regions in order to optimize its impact on enhancing fear extinction memory consolidation in a population with known fear extinction deficiencies: post-traumatic stress disorder (PTSD). 250 subjects will take part in this research study across UTHealth Houston. The study will include preliminary screenings, baseline visits, and experimental visits across four days Type: Interventional Start Date: Feb 2022 |
Fear and Avoidance in PTSD Patients
The University of Texas Health Science Center, Houston
Post Traumatic Stress Disorder
The purpose of this research study is to study how the brain learns to avoid certain
stimuli or situations using an experimental paradigm. The big goal is to measure brain
responses and subject's feelings and expectations when they are learning to actively
avoid experimental stimuli, and how fear e1 expand
The purpose of this research study is to study how the brain learns to avoid certain stimuli or situations using an experimental paradigm. The big goal is to measure brain responses and subject's feelings and expectations when they are learning to actively avoid experimental stimuli, and how fear extinction learning and monetary cost can change how and when subjects are to avoid. Type: Interventional Start Date: Sep 2021 |
Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease
Peggy C Nopoulos
Huntington's Disease
Huntington's Disease (HD) is an autosomal dominant disease manifested in a triad of
cognitive, psychiatric, and motor signs and symptoms. HD is caused by a triplet repeat
(CAG)expansion in the gene Huntingtin (HTT). This disease has classically been
conceptualized as a neurodegenerative disease. Ho1 expand
Huntington's Disease (HD) is an autosomal dominant disease manifested in a triad of cognitive, psychiatric, and motor signs and symptoms. HD is caused by a triplet repeat (CAG)expansion in the gene Huntingtin (HTT). This disease has classically been conceptualized as a neurodegenerative disease. However, recent evidence suggests that abnormal brain development may play an important role in the etiology of HD. Huntingtin (HTT)is expressed during development and through life. In animal studies, the HTT gene has been shown to be vital for brain development. This suggests that a mutant form of HTT (gene-expanded or CAG repeats of 40 and above) would affect normal brain development. In addition, studies in adults who are gene-expanded for HD, but have not yet manifested the illness, (pre-HD subjects) have significant changes in the structure of their brain, even up to 20 years before onset of clinical diagnosis. How far back these changes are evident is unknown. One possibility is that these brain changes are present throughout life, due to changes in brain development,though initially associated with only subtle functional abnormalities. In an effort to better understand the developmental aspects of this brain disease, the current study proposes to evaluate brain structure and function in children, adolescents, and young adults (ages 6-30) who are at risk for developing HD - those who have a parent or grandparent with HD. Brain structure will be evaluating using Magnetic Resonance Imaging (MRI) with quantitative measures of the entire brain, cerebral cortex, as well as white matter integrity via Diffusion Tensor Imaging. Brain function will be assessed by cognitive tests, behavioral assessment, and physical and neurologic evaluation. Subjects that are gene-expanded (GE) will be compared to subjects who are gene non-expanded (GNE). Changes in brain structure and/or function in the GE group compared to the GNE group would lend support to the notion that this disease has an important developmental component. Type: Observational Start Date: Jul 2005 |
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and1
The University of Texas Health Science Center, Houston
Bipolar II Disorder
Depression, Bipolar
Suicidality
The purpose of the study is to assess the safety and acceptability of up to two
sequential administrations of 25 mg psilocybin with additional therapeutic support in
decreasing suicidality in patients with Bipolar Disorder (BD II) depression. expand
The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression. Type: Interventional Start Date: Mar 2025 |
Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
Ultragenyx Pharmaceutical Inc
Glycogen Storage Disease Type Ia
The main objective of this observational study is to evaluate the long-term safety and
effectiveness of DTX401 for at least 10 years after DTX401 administration. expand
The main objective of this observational study is to evaluate the long-term safety and effectiveness of DTX401 for at least 10 years after DTX401 administration. Type: Observational Start Date: Nov 2024 |
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With1
Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
The goal of this study is to learn if people who receive intismeran autogene and
pembrolizumab after surgery are cancer-free longer than people who receive placebo and
pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab
after surgery can help prevent the cancer f1 expand
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment). Type: Interventional Start Date: Oct 2024 |
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
Pfizer
Migraine
The purpose of this study is to learn about the effect of a study medicine called
rimegepant in adolescents who have frequent migraine attacks.
Rimegepant is a tablet that dissolves when you put it on or under your tongue.
The study will enroll participants who have headache for 15 days (or more)1 expand
The purpose of this study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that dissolves when you put it on or under your tongue. The study will enroll participants who have headache for 15 days (or more) every month, of which 8 days (or more) of migraine every month, and each untreated attack lasts for an average of 4-72 hours In the 1st part of the study approximately half of the participants will receive a rimegepant tablet every other day, and approximately half of the participants will receive an inactive oral tablet (that looks the same as the rimegepant tablet) every other day. Participant experiences when they are taking the study medicine will be compared to when they are taking the inactive tablet. This will help to determine if the study medicine is safe and effective. The 1st phase of the study will last 3 months. In the 2nd part of the study all the participants who stay on study will receive rimegepant tablet every other day. This 2nd phase of the study will last 1 year. This will help determine if the study medicine is safe when taken for a long period. Those who will participate in both phases will have up to 19 visits at the study clinic, about one every 4 weeks (this may vary from 2 to 8 weeks interval during the study). Home health visits may occur as well. A health check and blood sample will be conducted at all visits. Participants will have to complete a daily diary to record the migraine attacks. Type: Interventional Start Date: Nov 2024 |
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Non1
Incyte Corporation
NonSegmental Vitiligo
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream
in pediatric participants with nonsegmental vitiligo. expand
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo. Type: Interventional Start Date: Jan 2025 |
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fib1
United Therapeutics
Progressive Pulmonary Fibrosis
Interstitial Lung Disease
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil
in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period. expand
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period. Type: Interventional Start Date: Oct 2023 |
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pe1
AbbVie
Episodic Migraine
A migraine is a moderate to severe headache on one side of the head. A migraine attack is
a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light
and sound, or other symptoms. A number of treatments are available for adults with
migraine but there are limited approve1 expand
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for pediatric participants. The main goal of the study is to evaluate the safety and efficacy (how well treatment works) of a low-dose and high-dose of atogepant in pediatric participants between the ages of 6 and 17. Atogepant is a medicine currently approved to treat adults with migraine (0 to 14 migraine days per month) and is being studied in pediatric participants between the ages of 6 and 17 with a history of episodic migraine. This is a Phase 3, randomized, double-blind study of atogepant in participants with a history of episodic migraine with an open-label pharmacokinetic substudy. Eligible participants will be randomized into 6 different groups. Participants between the ages of 12 and 17 will be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. Participants between the ages of 6 and 11 will also be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. The specific atogepant doses to be used in participants between the ages of 6 and 11 will be determined after the PK substudy is complete. Around 450 participants will be enrolled in approximately 100 sites worldwide. Placebo, low-dose atogepant, and high-dose atogepant are given as a tablet to take by mouth once a day. At the end of Week 12, participants will either undergo a follow-up visit 4 weeks after last study treatment or join an extension study where they can continue to receive atogepant for another 52 weeks. There may be a bigger responsibility for participants in this study. Participants will attend regular visits during the study at a hospital or clinic. The effects of treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires. Type: Interventional Start Date: May 2023 |
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With A1
argenx
Active Idiopathic Inflammatory Myopathy
Myositis
Dermatomyositis
Polymyositis
Immune-Mediated Necrotizing Myopathy
This study's purpose is to measure the treatment response from efgartigimod PH20 SC
compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM).
Participants with the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing
myopathy (IMNM), or certain other subtypes o1 expand
This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM). Participants with the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or certain other subtypes of polymyositis (PM; including antisynthetase syndrome [ASyS]) will be included in the study. Treatment response will be measured by Total improvement score (TIS). Additional information can be found on https://myositis-study.com/. Type: Interventional Start Date: Oct 2022 |
ALTERRA Post-Approval Study
Edwards Lifesciences
Pulmonary Valve Insufficiency
Complex Congenital Heart Defect
Tetralogy of Fallot
Pulmonary Regurgitation
RVOT Anomaly
This study will monitor device performance and outcomes in subjects undergoing
implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra
Adaptive Prestent in the post-approval setting expand
This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting Type: Observational Start Date: May 2022 |
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallo1
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib
(ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube,
or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose
tumors are Cyclin E1 positive as determ1 expand
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay. Type: Interventional Start Date: Feb 2022 |
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
DiaMedica Therapeutics Inc
Acute Stroke
Ischemic Stroke
Stroke
This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase
alfa) in treating participants with moderate stroke severity, who present within 24 hours
of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This
study focuses on participants with limi1 expand
This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limited treatment options. Participants who have or will receive mechanical thrombectomy (MT) are not eligible for participation. Additionally, participants who have received fibrinolytics are excluded unless they experience a persistent neurological deficit of moderate severity six or more hours after fibrinolytic treatment. Participants considered for this trial should not be denied the use of standard of care (SoC) AIS therapies, such as fibrinolytics or MT, when appropriate. The double-blinded study will be randomized and placebo-controlled at up to approximately 100 sites. Type: Interventional Start Date: Nov 2021 |
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Se1
Medtronic Cardiovascular
Mitral Valve Regurgitation
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All
subjects enrolled with receive the study device. expand
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device. Type: Interventional Start Date: Oct 2017 |